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S160 Oral PresentationsIf PB CD34 was\ 10/mL on day 5, plerixafor (0.24 mg/kg sc) was
administered in the evening 5 and apheresis was commenced the
next day. If daily yield was \ 0.5  106CD34/kg, plerixafor was
added. In Dec 2009, the algorithm was changed to Plerixafor-2.
The dosing of G-CSF and plerixafor remained the same, however
the thresholds changed to if day 4 PB CD34 \ 10 for single or
\20/mL for multiple transplants, plerixafor was added. If day 1 yield
was\1.5  106 CD34/kg, or any subsequent daily yield was\ 0.5,
plerixafor was added.
In the 3 time periods, Jan-Dec 2008, there were 327 mobiliza-
tion attempts in 286 patients, Feb-Nov 2009, 228 mobilization at-
tempts in 224 pts, and Dec 2009-June 2010, 101 attempts in 100
pts. Costs of the mobilization and collection included drugs costs
(cyclophosphamide, G-CSF, GM-CSF and plerixafor), apheresis
and cryopreservation. Supportive care costs of transfusions, anti-
biotics, hospitalizations, nursing costs and patients personal costs
were not included. The details of the results are outlined in the
table. Plerixafor-2 shows a statistical improvement PBSC collec-
tions, increased number of patients reaching minimum and opti-
mal goals, less days of apheresis and total days of mobilization/
collection.
In conclusion, although the earlier identification of ineffective
PBSC mobilization and initiation of plerixafor (Plerixafor-2) in-
creases the costs of PBSC mobilization, more patients are able to
achieve the minimum and optimal goals of CD34 collection, failure
rates, number of days of apheresis and total days of mobilization/
collection are lower. It is unclear if upfront mobilization with plerix-
afor 1 G-CSF would result in further benefit.
Table 1. Results of Mobilization and Collection
Baseline2008 Plerixafor-1 Plerixafor-2 P valuePatients 286 224 100Mobilization
Attempts/
Remobilizations327/ 41 (14%) 228/ 4 (2%) 101/ 1 (1%)CD34 collected
- x106/kgMedian 5.34 6.04 7.72 <0.001Range 0-25.8 0.1-28.2 1.48-29.3Mean 5.66 6.86 8.16Collections
>4 x106/kg (%)223 (68%) 185 (81%) 93 (92%) <0.001Collections
>2x106/kg(%)261 (80%) 212 (93%) 99 (97%) <0.001Mobilization Failures 66 (20%) 16 (7%) 1 (1%) <0.001Days of ApheresisMedian 2 3 2 0.002Range 0-11 1-12 1-9Mean 2.6 3.1 2.5Total Days of
Mobilization/
CollectionMedian 8 8 6Range 4-28 4-25 4-22Mean 9 8.9 7.2 <0.001Total Cost
per patientMedian $12 500 $12 500 $21 000 <0.001Minimum $3000 $5000 $5500Maximum $146 750 $93 500 $89 750Mean $17 300 $21 686 $20 695Plerixafor Use 29 # (9%) 94 (41%) 60 (59%)Days- Median 5 3 2 <0.001Range 1-10 1-8 1-9Mean 5 3.3 2.6Bone Marrow
Harvest*3 0 0#All remobilizations were on the compassionate use protocol. Costs
were based on current pricing of plerixafor;
*Cost of bone marrow harvest not inclusded in costs per patient.GVH/GVL
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Cdk5 is a ubiquitously expressed serine/threonine kinase. Cdk5
and its obligate partners p35 and p39 are required for neuronal de-
velopment and migration. Activation of the Cdk5/p35 complex is as-
sociated with inflammatory disorders, but the contribution of Cdk5
activity to T cell activation has not been explored. Using a mouse
BMT model (B6/ B6D2F1), we reveal a critical role for Cdk5 in
the induction of GVHD.TCR stimulation leads to a rapid induction
of Cdk5/p35 expression and function, and Cdk5 activity is increased
in the spleen and intestine of mice with GVHD. To study the role of
Cdk5 in T cells, we generated chimeric mice (Cdk52/2C) by recon-
stituting irradiated B6mice with hematopoietic progenitors from the
liver and spleen of E16.5 Cdk51/1 and Cdk52/2 littermate embryos;
germ line deletion of the Cdk5 gene is embryonically lethal. BMT
using B6 Cdk52/2C donors and lethally irradiated F1 hosts resulted
in a dramatic reduction in mortality (25% vs. 92%) and systemic
GVHD (p \ 0.01) compared to mice receiving B6 Cdk51/1C
BMT. Similar findings were seen in GVHD across an isolated
MHC-II mismatch, but were less apparent in a MHC class I dispa-
rate model, suggesting that Cdk5 was functioning primarily through
CD41 T cells. Mixing studies in the B6/F1 model showed that
CDk5 expression in purified T cells (compared to BM) was predom-
inantly responsible for reduced GVHD, and while a survival advan-
tage was maintained in GVL experiments, Cdk52/2C BMT was
associated with more leukemic deaths. Functional characterization
of Cdk52/2C T cells showed modest reductions in T cell prolifera-
tion to host antigens, but no differences in cytokine production or
CTL activity. However, donor splenic T cell numbers were mark-
edly reduced on days 7, 10 and 14 after Cdk52/2C BMT (p \
0.01), findings that were associated with reductions in day 7 serum
IFNg levels. Further studies showed that Cdk5 phosphorylates the
actin modulator Coronin 1a on threonine 418. Activated Cdk52/2
T cells lack this post-translational modification, exhibit defective
TCR-induced actin polarization and reduced migration towards
CCL-19.Co-migration studies using flow cytometry and intravitalmi-
croscopy revealed significant reductions in homing of Cdk52/2C
T cells (CD4 . CD8) to spleen and lymph nodes, but once entered,
the migration speed of Cdk52/2 T cells was not altered. Collectively,
our data define a novel role for Cdk5 in lymphocyte biology and allo-
geneic T cell responses after BMT.27
VALIDATION OF THE NATIONAL INSTITUTES OF HEALTH (NIH) CONSEN-
SUS CRITERIA FOR CHRONIC GVHD (cGVHD) STAGING CORRELATED
WITH ESTABLISHED INDICATORS OF DISEASE SEVERITY AND PROGNOSIS
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Background: In 2005, the NIH Consensus Project proposed the
cGVHD severity score to standardize clinician evaluation and stag-
ing of cGVHD.This analysis was conducted to validateNIH scoring
variables as adequate determinants of disease severity.
Methods: 189 adults were enrolled on the prospective NCI cross-
sectional cGVHDnatural history study between 2004-2010.Median
age was 46 yrs (18–70), median time from transplant was 35 mos
